Partnerships - Evox Therapeutics

Degenerative diseases of the central nervous system are one of the enduring medical challenges of our time. Their complexity has long prevented effective therapeutic intervention, leaving a devastating impact on patients and their families.

Evox is pioneering gene editing in the brain to stop the pathological chain reaction of neurodegenerative diseases, and we are seeking partners who share our commitment to ushering in a new era of genetic medicines for the brain.

Our pipeline: de-risked genetic targets in the CNS

Our internal pipeline is focused on silencing the genetic drivers that are the clearest and most therapeutically accessible targets of neurodegeneration. We are rapidly advancing our programs with a clear path to the clinic.

Huntington’s Disease

Our lead program targets MSH3, having the potential to stop disease progression in patients with mid- and late-stage HD and prevent disease onset in presymptomatic individuals.

ALS and SCA2

Our second program targets the silencing of ATXN2, a well-defined disease accelerator, to stop disease progression and preserve motor neuron function in patients.

New partnering opportunities in CNS

We are actively seeking collaborations to expand our work in the central nervous system. Our scientific and strategic interests include:

New genetic targets

We are looking for partners with deep expertise in the biology of other neurodegenerative diseases to identify and prosecute novel, de-risked genetic targets.

Accelerating development

We are open to partnerships that can help accelerate the development of our in-house CNS assets through unique capabilities or expertise.

Why partner with Evox for CNS therapeutics?

Our exosome-based therapies are specifically designed to meet the need for safer and more effective genetic medicines for the CNS. The brain is uniquely vulnerable to the toxicity risks of viral- and LNP-based genetic medicines. Our platform offers a clearly differentiated and clinically supported safety profile, providing a versatile and non-immunogenic way to access intracellular targets within the brain.

Opportunities beyond the CNS

While our primary focus is the CNS, our platform has been substantially validated in other tissues. We are open to discussing partnerships that leverage our technology to solve significant delivery challenges for genetic targets outside the central nervous system.